Our prior work found that AUCs from the BCRAT, BCSC, BRCAPRO, and BRCAPRO + BCRAT models were all considerably lower for HER2 + and triple-negative breast cancers (AUC range 0.513–0.585) than for ER/PR+HER2 − disease (AUC range 0.605–0.629) [10]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.